Increased Macrophage Migration Inhibitory Factor (MIF) in the Sera of Patients with Extensive Alopecia Areata  by Shimizu, Tadamichi et al.
mucosa of rare patients to resist pathogenic Dgs3 antibodies.
Such a mechanism would also explain the ®nding in the dog
patient (described above) with PV and no apparent PF lesions
(Olivry et al, 1992). Even though this explanation is still
speculative, in-depth analysis of such unusual cases will provide
us with further insight into the pathophysiology of pemphigus.
Furthermore, the elucidation of a mechanism leading to
``resistance'' to pathogenic antibodies would represent a potent
tool to develop the novel therapeutic strategies pemphigus
patients need.
In conclusion, we report a patient with features of both PF
and PV, including skin blisters in suprabasilar as well as a
subcorneal localization, but without mucosal involvement. This
represents, to the best of our knowledge, the ®rst example in
which concomitant PF and PV lesions are depicted within the
same location and more importantly, the ®rst example in
humans that provides evidence for the presence of circulating
pathogenic Dsg3 antibodies despite lack of mucosal involve-
ment. Even though such cases are probably very rare, they will
hopefully provide the key for a better understanding of the
pathophysiology of pemphigus.
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Increased Macrophage Migration Inhibitory Factor (MIF) in
the Sera of Patients with Extensive Alopecia Areata
To the Editor:
The pathogenesis of alopecia areata is still uncertain. The immune
system has been implicated in the pathogenesis of alopecia areata
and certain immunomodulatory cytokines play an important role in
this disease. The contribution of cytokines thought to be involved
in the pathogenesis of extensive alopecia areata has been studied.
Several lines of clinical and experimental data point towards
cytokines such as interleukin (IL)-1 and tumor necrosis factor
(TNF)-a, which may be crucial inducers of hair loss in alopecia
areata. For example, IL-1 has been shown to inhibit hair growth
in vitro and may be one of the factors triggering the arrest of hair
growth in vivo (Harmon and Nevins, 1993). TNF-a also inhibits
1Equal contribution.
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hair follicle growth in vitro (Philpott et al, 1996). Thus, IL-1 and
TNF-a may play a role in the pathophysiology of in¯ammatory
hair loss in alopecia areata.
MIF is the ®rst lymphokine reported to prevent the random
migration of macrophages (Bloom and Bennett, 1966). A recent
®nding demonstrated that MIF functions as an initiator of
in¯ammation and the immune response by the regulation of a
number of proin¯ammatory cytokines, including TNF-a and IL-1
(Calandra et al, 1994). In human in¯ammatory diseases, MIF has a
regulatory role in acute respiratory distress syndrome, asthma, and
rheumatoid arthritis. In skin diseases, we have reported that MIF
production by peripheral blood mononuclear cells was markedly
upregulated in patients with atopic dermatitis and that increased
serum MIF levels were observed (Shimizu et al, 1999). We
postulated that MIF might play a key role in the pathogenesis of
extensive alopecia areata. In this study, we analyzed the serum MIF
concentration in patients with alopecia areata and normal healthy
individuals.
The study group composed of 27 patients with extensive
alopecia areata (with >50% bald area of the scalp; aged from 13 to
32 y, mean age 21.3 6 1.3 y; nine males and 18 females; the
duration of their alopecia areata was between 6 mo and 11 y, mean
3.8 y), 11 patients with mild alopecia areata (1±3 patchy hair loss
lesions with < 10% bald area of the scalp and with an inactive
condition; aged from 11 to 36 y, mean age 24.9 6 1.6 y; two
males and nine females; the duration of their alopecia areata was
between 2 mo and 3 y, mean 1.2 y), and 12 normal healthy
individuals (aged from 18 to 45 y, mean age 29.3 6 1.8 y; four
males and eight females). None of the patients was having topical
immunotherapy, systemic, or topical steroids therapy at the time of
the study. Eight patients with extensive alopecia areata showed
successful hair regrowth (100% hair regrowth) when treated with
topical sensitizer (squaric acid dibutylester or diphencyprone) and
the serum was obtained at least 1 mo after the ®nal topical therapy.
The serum level of MIF was measured by enzyme-linked
immunosorbent assay (ELISA) as described previously (Shimizu et
al, 1999). MIF levels were compared using the Student's t test (p
< 0.05). Five patients' scalp biopsy specimens with an extensive
alopecia areata were immunohistochemically examined for MIF
immunoreactivity. Sections were stained using an avidin-biotin-
peroxidase complex procedure using a Vector ABC kit according
to the manufacturer's protocol (Shimizu et al, 1996).
The mean serum MIF concentration in extensive alopecia areata
patients (n = 27) was 50.6 6 5.7 ng per ml (mean 6 SE), whereas
that of mild alopecia areata (n = 11) or healthy individuals (n = 12)
was 15.1 6 2.1 ng per ml or 8.9 6 1.3 ng per ml, respectively (p
< 0.001) (Fig 1A). In eight extensive alopecia areata patients serum
MIF was also examined before (>50% bald area of the scalp) and
after hair regrowth (100% hair regrowth of the scalp). The mean
serum MIF concentration before treatment was 55.8 6 14.9 ng
per ml, whereas that after the treatment was 15.7 6 2.8 ng per ml
(p < 0.01) (Fig 1B). Immunohistochemical studies with an anti-
MIF antibody were positive in perifollicular-in®ltrated lympho-
cytes of telogen hair follicles in patients with extensive alopecia
areata (Fig 2).
The results presented here demonstrate that the mean levels of
MIF in the sera were signi®cantly elevated in patients with
extensive alopecia areata. Alopecia areata is considered to be a T
cell-mediated autoimmune disease involving the hair follicle,
which is characterized by peribulbar in®ltration by activated T
cells (Bodemer et al, 2000). Although the function of these T cells
in the pathogenesis is still unknown, cytokines released from T cells
are important mediators leading to hair loss in alopecia areata. It is
speculated that MIF in in¯ammatory diseases may be produced by
multiple cellular sources such as activated T lymphocytes and
monocytes. On the basis of our immunohistochemical results, we
speculate that activated T cells might be a potential source of serum
MIF. MIF is known to stimulate the production of proin¯amma-
tory cytokines such as IL-1 and TNF-a by macrophage and vice
versa (Bacher et al, 1996). From the data available to date, together
with these results, we believe that a positive feedback loop may be
the cause of the in¯ammatory interaction between IL-1, TNF-a,
and MIF in this disease. It is known that the proin¯ammatory
mediators IL-1 and TNF-a are potent inhibitors of hair follicle cell
proliferation with a concomitant inhibition of hair growth (Philpott
et al, 1996). Therefore, these in¯ammatory cytokines may be
implicated in the induction or continuation of damage of hair
follicles and MIF may play an important part in the pathophysiol-
ogy of in¯ammatory hair loss conditions such as alopecia areata.
Whereas alopecia areata is a common disease, treatment of its
extensive form is dif®cult and its outcome is not easily predicted.
Recent work demonstrated that anti-MIF antibodies have a potent
therapeutic action in the severe in¯ammatory condition such as
murine hepatitis (Kobayashi et al, 1999). We assume that the
elevated serum levels of MIF may re¯ect the in¯ammatory
symptoms in extensive alopecia areata and that control of MIF
production may have important therapeutic implications.
Figure 1. Serum MIF contents of alopecia areata patients. (A)
Serum MIF concentration in alopecia areata patients and healthy
individuals. ELISA measured the serum level of MIF for patients with
extensive alopecia areata (n = 27), patients with mild alopecia areata
(n = 11), or healthy individuals (n = 12). Serum MIF levels were
signi®cantly increased in extensive alopecia areata compared with mild
alopecia areata or healthy controls (p < 0.001). (B) Serum MIF levels
before (>50% bald area of the scalp) and after hair regrowth (100% hair
regrowth of the scalp; 6 mo to 2 y, mean duration 12.5 6 2.1 mo)
(n = 8). The mean serum MIF concentration before treatment was
55.8 6 14.9 ng per ml, whereas that of after the hair regrowth was
15.7 6 2.8 ng per ml (p < 0.01).
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Evidence for Extensive Locus Heterogeneity in Naxos Disease
To the Editor:
Naxos disease is a rare autosomal recessive disease that consists of an
associated triad of woolly hair, thickened palms and soles
(keratoderma), and heart involvement. The hair phenotype is
unique, characterized by congenital woolly, curly, rough, and light
colored scalp hair and sparse eyebrows. The nonepidermolytic
keratoderma appears during the ®rst years of life and involves mainly
pressure areas in the palms and soles. The heart manifestations appear
during the teenage years and are severe and progressive and may end
with arrhythmia and premature sudden death. The disease was
originally described in individuals from the Greek Island Naxos by
Protonotarios et al in 1986 and by Barker et al in 1998. In 1998,
Carvajal-Huerta reported patients from Guayaquil, Ecuador with a
similar autosomal recessive triad, with combined epidermolytic
palmoplantar keratoderma with woolly hair and dilated cardiomyo-
pathy, and described the skin manifestations. Another family with
the autosomal dominant association of nonepidermolytic palmo-
plantar keratoderma, woolly hair, and dilated right ventricle was
reported by Tosti et al (1994) in an Italian family. Recently, Coonar
et al (1998) mapped the gene for the Greek families (Naxos disease)
to 17q21, and a mutation in the plakoglobin gene was identi®ed as
responsible for the disease in the Greek families (McKoy et al, 2000).
In the Ecuadorian family, a mutation in the desmoplakin gene was
found to be responsible for the disease (Norgett et al, 2000). In this
study, we report the clinical ®ndings in two new Arab families with
Naxos disease originating from villages near Jerusalem. Importantly,
we have excluded both plakoglobin and desmoplakin as the
candidate genes in these families. Furthermore, we have analyzed
several other regions harboring candidate genes of interest, and
found no evidence for linkage.
The pedigree structures of the two families are shown in Fig 1(a,
b). The history and clinical examination of patients from families A
and B included the congenital appearance of woolly, curly, rough,
light colored scalp hair with sparse eyebrows, axillary, and pubic hair
(Fig 1c). Skin involvement included palmoplantar keratoderma
(Figs 1d, e) starting around age 3, as well as follicular keratosis on
extensor arms, shins, back, and cheeks, lichenoid papules mainly on
the lower shins and psoriasiform keratosis. A plantar skin biopsy
Figure 2. Immunohistochemical analysis of MIF expression in an extensive alopecia areata scalp biopsy. Tissue specimens were stained with
a Vector ABC staining kit using polyclonal antihuman MIF antibody. (A) Intense MIF staining was observed in the perifollicular-in®ltrated
lymphocytes of telogen hair follicles. Hair follicle MIF staining was also apparent. (B) No speci®c positive staining was observed using the tissue sample
stained with preimmune rabbit IgG. Scale bar: 50 mm.
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